VICONEL contributes to the Ndovu study, a multi-country initiative led by the University of Nairobi and focused on improving clinical management of confirmed viral drug resistance to dolutegravir (DTG) as the main anchor drug used globally to treat HIV. In the Ndovu randomised controlled trial, people taking DTG with viraemia and confirmed resistance to DTG are assigned 1:1 to either continued DTG-based antiretroviral therapy (ART) or switch to ritonavir-boosted darunavir-based ART in order to compare treatment outcomes at 12 months.

Ndovu is conducted in Kenya, Tanzania, Mozambique, and Lesotho. In Lesotho, all Ndovu operations have been nested within the VICONEL framework.

Funding

Gates Foundation 

Principal Investigator

Dr Loice Ombajo 

Project Leads, Ndovu Lesotho

Dr. Irene Ayakaka

Prof. Niklaus Labhardt

Dr. Anna Klicpera

Dr. Blaise Lukau